Global Congenital Heart Diseases Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Congenital Heart Diseases Market Research Report 2024
Congenital diseases are disorders in a newborn due to certain genetic factors (and sometimes in association with the environment) that often results in malformations or underdeveloped organs. Congenital Heart Diseases (CHD) results in malformed or undeveloped heart that presents in a newborn with breathing and circulation disorders. According to Lancet medical journal, CHD caused death of 0.22 million individuals and newborns globally in the year 2010. CHD was earlier erroneously associated with premature births, the association has no direct correlation with all forms of CHD and is mainly one of the many factors that can cause it. The genetic factors causing CHD consist of chromosomal errors in fertilization and the following meiotic division, these includelarge chromosomal defects in trisomal chromosomes; small chromosomal defects like microdeletion of long/short arm of chromosome and random/environmentally induced mutation of heart muscle cell proteins, or associated proteins etc. The environmental factors like rubella infections, thalidomide drugs, metals (lithium, lead, mercury, etc), chronic illness in the mother (systemic lupus, diabetes, phenylketonuria, etc). Embryological changes, hormonal changes in the mother and certain birth deficiencies can also cause CHD and other birth defects in children. Besides these, according to some medical research reports, maternal obesity increased the chances of CHD in newborns; obesity was shown to increase the risk of previously hidden genetic traits of CHD in the new born children of such obese mothers.
According to MRAResearch’s new survey, global Congenital Heart Diseases market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Congenital Heart Diseases market research.
The treatment of CHD varies from case to case; genetic testing/screening is mandatory in case the doctor suspects a genetic cause for the disease, in developed countries this is done for all newborns. The next step would be surgery or drug treatment, again this depends upon the severity of the condition. In most cases CHD presents itself as serious conditions with high risk of complications, hence surgery is the most followed procedure. In certain disorders like ASD a pediatric surgeon may ask the parents of a CHD child to wait for the child’s growth as ASD is known to disappear gradually, a surgery is performed if ASD persists after the child’s growth. Certain cases also require multiple surgeries and stenting in order to restore a malformed tract in the lungs, etc. Drugs like diuretics are given to regulate vasoconstriction that alleviates deoxygenation and helps remove toxins from the body, besides reducing the heartbeat.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Congenital Heart Diseases market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer
Abbott Laboratories
Eli Lilly
Ranbaxy Pharmaceutical
Segment by Type
Hypoplasia
Obstructive
Septal Defects
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Congenital Heart Diseases report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Congenital Heart Diseases market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Congenital Heart Diseases market research.
The treatment of CHD varies from case to case; genetic testing/screening is mandatory in case the doctor suspects a genetic cause for the disease, in developed countries this is done for all newborns. The next step would be surgery or drug treatment, again this depends upon the severity of the condition. In most cases CHD presents itself as serious conditions with high risk of complications, hence surgery is the most followed procedure. In certain disorders like ASD a pediatric surgeon may ask the parents of a CHD child to wait for the child’s growth as ASD is known to disappear gradually, a surgery is performed if ASD persists after the child’s growth. Certain cases also require multiple surgeries and stenting in order to restore a malformed tract in the lungs, etc. Drugs like diuretics are given to regulate vasoconstriction that alleviates deoxygenation and helps remove toxins from the body, besides reducing the heartbeat.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Congenital Heart Diseases market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Abbott Laboratories
Eli Lilly
Ranbaxy Pharmaceutical
Segment by Type
Hypoplasia
Obstructive
Septal Defects
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Congenital Heart Diseases report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices